Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection

Br J Haematol. 2022 Mar;196(5):1170-1174. doi: 10.1111/bjh.17957. Epub 2021 Nov 11.

Scott J C Pallett^{1

2}, Rachel Wake^{1

3}, Jonathan Youngs¹, Cassie Pope^{1

3}, Ngee Keong Tan⁴, Joshua Taylor⁴, Lois Hawkins¹, Adam A Witney³, Kenneth G Laing³, Irene M Monahan³, Melek Akay⁵, Alison Cox⁶, Elisabetta Groppelli³, Peter Kelleher⁶, Paul Miller⁵, Tihana Bicanic^{1

3}

¹ Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK.
² Centre of Defence Pathology, Royal Centre for Defence Medicine, Edgbaston, Birmingham, UK.
³ Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London, UK.
⁴ South West London Pathology, Jenner Wing, St. George's Hospital, London, UK.
⁵ Department of Haematology, St George's University Hospitals NHS Foundation Trust, London, UK.
⁶ Centre for Immunology and Vaccinology, Department of Medicine, Imperial College London, London, UK.

No abstract available

Keywords: COVID-19; SARS-CoV-2; immune reconstitution; lymphoma; recurrence.

Publication types